Clinical Impact of Drug Adherence of Tyrosine Kinase Inhibitors in Children with Ph-Positive Acute Lymphoblastic Leukemia
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose This study aimed to explore the impact of ABL1–tyrosine kinase inhibitors (TKIs) adherence on the survival of chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) children and clarify the potential predictors of patients’ prognosis from TKIs intake practices.Materials and Methods Ninety newly diagnosed Ph+ ALL patients who received TKIs were enrolled. We collected the baseline characteristics and adverse events in all children; moreover, TKIs adherence was measured by an eight-item Morisky medication adherence scale (MMAS-8). Progression-free survival (PFS) and overall survival (OS) analysis were performed, and risk factors for PFS and OS were evaluated.Results Among all patients, 69 cases were regarded as adherers, while 21 were non-adherers. The median duration of TKIs interruption was significantly prolonged in the non-adherence group than in the adherence group (13 [0-101] vs. 56 [11-128], p < 0.001). Additionally, dose reduction occurred in 55.2% of non-adherers versus 23.0% of adherers (p=0.002). The PFS and OS in adherers were significantly higher versus non-adherers (p=0.020 and p=0.039). MMAS-8 score was an independent risk factor for PFS (p=0.010) and OS (p=0.031). Among non-adherers, the median OS was only 23.1% (4.2%-42%) in patients aged ≤ 10 years versus 54.4% (38.8%-70%) in adolescents. Most of the patients who experienced TKIs non-adherence suffered pancytopenia.Conclusion TKIs adherence during treatment significantly influenced the survival of pediatric Ph+ ALL patients, and non-adherers with age ≤ 10 years were more vulnerable to TKIs disruption. The cumulative TKIs dose should be especially emphasized to patients with age ≤ 10 years, which may result in an inferior achievement of relevant treatment milestones.
Abstract
Purpose This study aimed to explore the impact of ABL1–tyrosine kinase inhibitors (TKIs) adherence on the survival of chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) children and clarify the potential predictors of patients’ prognosis from TKIs intake practices.Materials and Methods Ninety newly diagnosed Ph+ ALL patients who received TKIs were enrolled. We collected the baseline characteristics and adverse events in all children; moreover, TKIs adherence was measured by an eight-item Morisky medication adherence scale (MMAS-8). Progression-free survival (PFS) and overall survival (OS) analysis were performed, and risk factors for PFS and OS were evaluated.Results Among all patients, 69 cases were regarded as adherers, while 21 were non-adherers. The median duration of TKIs interruption was significantly prolonged in the non-adherence group than in the adherence group (13 [0-101] vs. 56 [11-128], p < 0.001). Additionally, dose reduction occurred in 55.2% of non-adherers versus 23.0% of adherers (p=0.002). The PFS and OS in adherers were significantly higher versus non-adherers (p=0.020 and p=0.039). MMAS-8 score was an independent risk factor for PFS (p=0.010) and OS (p=0.031). Among non-adherers, the median OS was only 23.1% (4.2%-42%) in patients aged ≤ 10 years versus 54.4% (38.8%-70%) in adolescents. Most of the patients who experienced TKIs non-adherence suffered pancytopenia.Conclusion TKIs adherence during treatment significantly influenced the survival of pediatric Ph+ ALL patients, and non-adherers with age ≤ 10 years were more vulnerable to TKIs disruption. The cumulative TKIs dose should be especially emphasized to patients with age ≤ 10 years, which may result in an inferior achievement of relevant treatment milestones.
참고문헌 (20)
- Inaba H, "Pediatric acute lymphoblastic leukemia", Haematologica, 105, pp.2524~2539 (2020)
- Jeha S, "Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation : St Jude Total Therapy Study 16", J Clin Oncol, 37, pp.3377~3391 (2019)
- Leoni V, "Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia", Haematologica, 100, pp.295~299 (2015)
- Shen S, "Effect of dasatinib vs imatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia : a randomized clinical trial", JAMA Oncol, 6, pp.358~366 (2020)
- Slayton WB, "Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome-positive acute lymphoblastic leukemia : results of Children’s Oncology Group Trial AALL0622", J Clin Oncol, 36, pp.2306~2314 (2018)
- Jabbour E, "Treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia-fom intensive chemotherapy combinations to chemotherapy-free regimens : a review", JAMA Oncol, 8, pp.1340~1348 (2022)
- De Geest S, "ESPACOMP Medication Adherence Reporting Guideline(EMERGE)", Ann Intern Med, 169, pp.30~35 (2018)
- Yang W, "Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia(CCCG-ALL-2015) : an open-label, multicentre, randomised, phase 3, non-inferiority trial", Lancet Oncol, 22, pp.1322~1332 (2021)
- Tang J, "Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation", Blood, 138, pp.331~343 (2021)
- Woodard L, "Comparison of collaborative goal setting with enhanced education for managing diabetes-associated distress and hemoglobin A1c levels : a randomized clinical trial", JAMA Netw Open, 5, pp.e229975~ (2022)
- Morisky DE, "Predictive validity of a medication adherence measure in an outpatient setting", J Clin Hypertens(Greenwich), 10, pp.348~354 (2008)
- Morisky DE, "Improving the measurement of self-reported medication nonadherence : response to authors", J Clin Epidemiol, 64, pp.255~257 (2011)
- Berlowitz DR, "Effect of intensive blood-pressure treatment on patient-reported outcomes", N Engl J Med, 377, pp.733~744 (2017)
- Bress AP, "Cost-effectiveness of intensive versus standard blood-pressure control", N Engl J Med, 377, pp.745~755 (2017)
- Geissler J, "Factors influencing adherence in CML and ways to improvement : results of a patient-driven survey of 2546patients in 63 countries", J Cancer Res Clin Oncol, 143, pp.1167~1176 (2017)
- Mancini J, "Adherence to leukemia maintenance therapy : a comparative study among children, adolescents, and adults", Pediatr Hematol Oncol, 29, pp.428~439 (2012)
- Millot F, "Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase", Pediatr Blood Cancer, 61, pp.355~357 (2014)
- Govani SM, "Defining an optimal adherence threshold for patients taking subcutaneous anti-TNFs for inflammatory bowel diseases", Am J Gastroenterol, 113, pp.276~282 (2018)
- Watanabe JH, "Revisiting the medication possession ratio threshold for adherence in lipid management", Curr Med Res Opin, 29, pp.175~180 (2013)
- De Las Cuevas C, "Psychometric properties of the eight-item Morisky Medication Adherence Scale(MMAS-8)in a psychiatric outpatient setting", Int J Clin Health Psychol, 15, pp.121~129 (2015)